Mark Plavsic is CTO at Aura Biosciences, Inc. (AURA). They have made 6 open-market trades across 2 companies since 2022, most recently 2026-03-02.
CIK 0001868719
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AURA | 243,736 | $1.5M |
| FATE | 123,705 | $220K |
| Total | $1.7M |
Shares reported on the most recent Form 4, priced at the 2026-03-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AURA | SELL | 2026-02-17 | 2026-02-17 | $5.05 | $80K | +12.6% | +25.8% | +43.0% |
| AURA | SELL | 2025-10-16 | 2025-10-16 | $6.35 | $155K | +4.1% | -10.1% | -14.1% |
| AURA | SELL | 2025-02-18 | 2025-02-18 | $7.75 | $17K | -3.4% | -4.3% | -23.6% |
| AURA | SELL | 2024-10-16 | 2024-10-16 | $9.85 | $145K | +7.2% | -7.5% | -26.2% |
| FATE | SELL | 2023-01-10 | 2023-01-11 | $5.24 | $18K | -5.2% | +8.6% | -1.6% |
| FATE | SELL | 2022-07-05 | 2022-07-06 | $24.61 | $183K | +7.3% | +16.9% | -16.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.